Abstract
Objective
To investigate the value of post-treatment diffusion-weighted imaging (DWI) for predicting disease progression following concurrent chemoradiotherapy (CCRT) for cervical cancer.
Methods
This retrospective study included 100 consecutive patients with locally advanced cervical cancer who underwent T2-weighted imaging (T2WI) and DWI 1 month after completing CCRT. The presence of residual tumour was independently determined on T2WI and T2WI plus DWI. The imaging findings were compared regarding prediction of disease progression.
Results
Disease progressed in 24 patients during follow-up. Forty-one and 22 patients were determined as having residual tumour on T2WI and T2WI plus DWI, respectively. Regarding prediction of disease progression, positive predictive values of imaging findings on T2WI and T2WI plus DWI were 32.7 % and 54.4 %, respectively, 1 year after treatment (P = 0.004), 37.2 % and 73.0 %, respectively, 2 years after treatment (P < 0.001), and 39.3 % and 72.7 %, respectively, 3 years after treatment (P = 0.001). Multivariate Cox regression analysis revealed that the presence of residual tumour on T2WI plus DWI was the independent predictor of disease progression (hazard ratio = 6.34, P < 0.001).
Conclusion
Post-treatment DWI offers an incremental value to T2WI in predicting disease progression after CCRT of cervical cancer.
Key Points
• T2WI alone has limited prognostic value after CCRT of cervical cancer.
• Adding DWI to T2WI improves prediction of disease progression after CCRT.
• Residual tumour on post-treatment T2WI plus DWI is associated with disease progression.
Similar content being viewed by others
Abbreviations
- ADC:
-
Apparent diffusion coefficient
- CCRT:
-
Concurrent chemoradiotherapy
- DWI:
-
Diffusion-weighted imaging
- EBRT:
-
External beam radiotherapy
- FIGO:
-
International Federation of Gynecology and Obstetrics
- FOV:
-
Field of view
- HR:
-
Hazard ratio
- ICR:
-
Intracavitary brachytherapy
- LN:
-
Lymph node
- NPV:
-
Negative predictive value
- MRI:
-
Magnetic resonance imaging
- PPV:
-
Positive predictive value
- SCC:
-
Squamous cell carcinoma
- SI:
-
Signal intensity
- T2WI:
-
T2-weighted imaging
References
Rose PG, Bundy BN, Watkins EB et al (1999) Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 340:1144–1153
Friedlander M, Grogan M (2002) Guidelines for the treatment of recurrent and metastatic cervical cancer. Oncologist 7:342–347
Morice P, Uzan C, Zafrani Y, Delpech Y, Gouy S, Haie-Meder C (2007) The role of surgery after chemoradiation therapy and brachytherapy for stage IB2/II cervical cancer. Gynecol Oncol 107:S122–S124
Touboul C, Uzan C, Mauguen A et al (2010) Prognostic factors and morbidities after completion surgery in patients undergoing initial chemoradiation therapy for locally advanced cervical cancer. Oncologist 15:405–415
Schwarz JK, Siegel BA, Dehdashti F, Grigsby PW (2007) Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma. JAMA 298:2289–2295
Tangjitgamol S, Katanyoo K, Laopaiboon M, Lumbiganon P, Manusirivithaya S, Supawattanabodee B (2014) Adjuvant chemotherapy after concurrent chemoradiation for locally advanced cervical cancer. Cochrane Database Syst Rev 12, CD010401
Balleyguier C, Sala E, Da Cunha T et al (2011) Staging of uterine cervical cancer with MRI: guidelines of the European Society of Urogenital Radiology. Eur Radiol 21:1102–1110
Vincens E, Balleyguier C, Rey A et al (2008) Accuracy of magnetic resonance imaging in predicting residual disease in patients treated for stage IB2/II cervical carcinoma with chemoradiation therapy: correlation of radiologic findings with surgicopathologic results. Cancer 113:2158–2165
Koh DM, Collins DJ (2007) Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol 188:1622–1635
Hamstra DA, Rehemtulla A, Ross BD (2007) Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol 25:4104–4109
Naganawa S, Sato C, Kumada H, Ishigaki T, Miura S, Takizawa O (2005) Apparent diffusion coefficient in cervical cancer of the uterus: comparison with the normal uterine cervix. Eur Radiol 15:71–78
Harry VN, Semple SI, Gilbert FJ, Parkin DE (2008) Diffusion-weighted magnetic resonance imaging in the early detection of response to chemoradiation in cervical cancer. Gynecol Oncol 111:213–220
Schreuder SM, Lensing R, Stoker J, Bipat S (2015) Monitoring treatment response in patients undergoing chemoradiotherapy for locally advanced uterine cervical cancer by additional diffusion-weighted imaging: A systematic review. J Magn Reson Imaging 42:572–94
Park MJ, Kim SH, Lee SJ, Jang KM, Rhim H (2011) Locally advanced rectal cancer: added value of diffusion-weighted MR imaging for predicting tumor clearance of the mesorectal fascia after neoadjuvant chemotherapy and radiation therapy. Radiology 260:771–780
Pecorelli S, Zigliani L, Odicino F (2009) Revised FIGO staging for carcinoma of the cervix. Int J Gynaecol Obstet 105:107–108
Haie-Meder C, Morice P, Castiglione M (2010) Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21:v37–v40
Siva S, Herschtal A, Thomas JM et al (2011) Impact of post-therapy positron emission tomography on prognostic stratification and surveillance after chemoradiotherapy for cervical cancer. Cancer 117:3981–3988
Padhani AR, Liu G, Koh DM et al (2009) Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 11:102–125
Kaur H, Silverman PM, Iyer RB, Verschraegen CF, Eifel PJ, Charnsangavej C (2003) Diagnosis, staging, and surveillance of cervical carcinoma. AJR Am J Roentgenol 180:1621–1631
Zand KR, Reinhold C, Abe H, Maheshwari S, Mohamed A, Upegui D (2007) Magnetic resonance imaging of the cervix. Cancer Imaging 7:69–76
Kinkel K, Ariche M, Tardivon AA et al (1997) Differentiation between recurrent tumor and benign conditions after treatment of gynecologic pelvic carcinoma: value of dynamic contrast-enhanced subtraction MR imaging. Radiology 204:55–63
Park JJ, Kim CK, Park SY, Park BK (2015) Parametrial invasion in cervical cancer: fused T2-weighted imaging and high-b-value diffusion-weighted imaging with background body signal suppression at 3 T. Radiology 274:734–741
Eifel PJ, Winter K, Morris M et al (2004) Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol 22:872–880
Grigsby PW, Siegel BA, Dehdashti F (2001) Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol 19:3745–3749
Acknowledgments
The scientific guarantor of this publication is Dr. Won Jae Lee. The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article. The authors state that this work has not received any funding. No complex statistical methods were necessary for this paper. Institutional Review Board approval was obtained. This retrospective study was approved by our institutional review board, with a waiver of the requirement for informed consent.
No study subjects or cohorts have been previously reported. Methodology: retrospective, diagnostic or prognostic study, performed at one institution.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Park, J.J., Kim, C.K. & Park, B.K. Prediction of disease progression following concurrent chemoradiotherapy for uterine cervical cancer: value of post-treatment diffusion-weighted imaging. Eur Radiol 26, 3272–3279 (2016). https://doi.org/10.1007/s00330-015-4156-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00330-015-4156-7